ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EVGN Evogene Ltd

0.6951
-0.0104 (-1.47%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Evogene Ltd NASDAQ:EVGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0104 -1.47% 0.6951 0.691 0.8998 0.7315 0.6706 0.70 25,365 05:00:10

Report of Foreign Issuer (6-k)

10/08/2017 12:34pm

Edgar (US Regulatory)




UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August, 2017
 
Commission File Number: 001-36187

EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F x Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 


CONTENTS
 
   Attached hereto and incorporated by reference herein are the following exhibits:
 
99.1
Press Release: Evogene Reports Second Quarter 2017 Financial Results.
 
99.2
Presentation Regarding DuPont Pioneer–Evogene Collaboration for the Development of Bio-stimulant Corn Products.
 
2

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



Date: August 10, 2017
 
EVOGENE  LTD.
(Registrant)

By: /s/ Alex Taskar
——————————————
Alex Taskar
Chief Financial Officer

3

 
EXHIBIT INDEX
 
EXHIBIT NO.
DESCRIPTION

4

1 Year Evogene Chart

1 Year Evogene Chart

1 Month Evogene Chart

1 Month Evogene Chart

Your Recent History

Delayed Upgrade Clock